Patients With Migraine Who Achieved a ≥75% Reduction in Monthly Migraine Days With Eptinezumab Treatment: Subgroup Analysis of PROMISE-1 and PROMISE-2

被引：0

作者：

Lipton, R. B. ^{[1
]}

Charleston, L. ^{[2
]}

Tassorelli, C. ^{[3
]}

Brevig, T. ^{[4
]}

Hirman, J. ^{[5
]}

Cady, R. ^{[6
]}

机构：

[1] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA

[2] Michigan State Univ, Dept Neurol & Ophthalmol, E Lansing, MI 48824 USA

[3] IRCCS C Mondino Fdn, Pavia, Italy

[4] H Lundbeck & Co AS, Copenhagen, Denmark

[5] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA

[6] Lundbeck La Jolla Res Ctr, San Diego, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P0312

引用

页码：113 / 114

页数：2